CD38 has been documented in r/r B-ALL malignant cells, and CD38 CAR-T cells were used to treat an r/r B-ALL patient who failed to respond to bispecific CD19/CD22 CAR-T cell therapy (Fig. 2). Here, CD22 is linked to acute lymphoblastic leukemia.